Seton Medical Center Uses Impella Heart Recovery Technology for Cardiovascular Procedure
May 24, 2018 | Seton News, Featured Employees
Seton Medical Center Cardiologist, Felix Millhouse, MD, performed the first cardiovascular procedure at the hospital using Impella®, the world’s smallest heart pump. The Impella is designed to provide minimally-invasive, temporary support for patients with heart failure. This technology will allow Seton to provide more comprehensive and advanced care options to patients in the Bay Area with advanced coronary disease. Impella allows patients to recover their natural heart function, which is ideal for quality of life, and has the potential to reduce costs in the healthcare system.
“Impella technology gives us a new way to treat patients who are very sick due to advanced heart failure or a heart attack,” said Dr. Millhouse. “It is a minimally-invasive treatment option, allowing the patient’s heart to rest and ultimately recover to improve their quality of life. This new technology furthers our commitment to providing patients comprehensive treatment options for heart failure.”
The Impella device is placed into the heart through a peripheral artery and will support the heart circulatory system during an elective high-risk percutaneous coronary intervention (PCI) procedure, called Protected PCI. It is also approved to treat cardiogenic shock, a condition where the heart fails to pump enough blood to vital organs and they begin to shut down. Cardiogenic shock typically happens during or after a heart attack. Impella works for the heart, allowing it to rest and recover while doctors place stents in the patient’s arteries to unblock them and increase blood flow.
“Seton is recognized as providing outstanding cardiovascular care in the region,” said Mark Fratzke, president and chief executive officer of Seton Medical Center. “Adding the Impella heart pump technology to our cardiovascular offerings means we can provide a new option to patients who may have been turned down for heart surgery or whose hearts are too weak to pump on their own after a heart attack.”
Impella is the only FDA-approved percutaneous hemodynamic support device determined to be safe and effective for the treatment of elective and emergent high risk patients. The device recently received expanded approval from the United States Food and Drug Administration (FDA).